Search

Your search keyword '"Santero, Marilina"' showing total 224 results
Start Over Author "Santero, Marilina"
224 results on '"Santero, Marilina"'

9. Self-management interventions for adults living with obesity to improve patient-relevant outcomes: An evidence map

Author

Sunol, Rosa, González-González, Ana Isabel, Valli, Claudia, Ballester, Marta, Seils, Laura, Heijmans, Monique, Poortvliet, Rune, van der Gaag, Marieke, Rocha, Claudio, León-García, Montserrat, Salas-Gama, Karla, de Guzman, Ena Niño, Kaloteraki, Chrysoula, Santero, Marilina, Spoiala, Cristina, Gurung, Pema, Moaddine, Saida, Wilemen, Fabienne, Cools, Iza, Bleeker, Julia, Kancheva, Angelina, Ertl, Julia, Laure, Tajda, Kancheva, Ivana, Veroniki, Areti Angeliki, Zevgiti, Stella, Beltrán, Jessica, Canelo-Aybar, Carlos, Zafra-Tanaka, Jessica Hanae, Seitidis, Georgios, Mavridis, Dimitris, Groene, Oliver, Alonso-Coello, Pablo, and Orrego, Carola

Published
2023
Full Text
View/download PDF

15. Efficacy of systemic oncological treatments in patients with advanced pancreatic cancer at high risk of dying in the short or medium-term: overview of systematic reviews

Author

Simancas Racines, Daniel, Hidalgo, Ricardo, Gutiérrez, Marta, Leache, Leire, Saiz, Luis C., Salazar, Josefina, Pérez-Bracchiglione, Javier, Salas-Gama, Karla, Antequera, Alba, Auladell-Rispau, Ariadna, Dorantes-Romandía, Rosario, Meade, Adriana G., Jesús Quintana, María, Requeijo, Carolina, Rodríguez-Grijalva, Gerardo, Santero, Marilina, Acosta-Dighero, Roberto, Solà, Ivan, Urrútia, Gerard, and Bonfill Cosp, Xavier

Published
2021
Full Text
View/download PDF

16. Risk of COVID-19 death for people with a pre-existing cancer diagnosis prior to COVID-19-vaccination:A systematic review and meta-analysis

Author

Steinberg, Julia, Hughes, Suzanne, Hui, Harriet, Allsop, Matthew J., Egger, Sam, David, Michael, Caruana, Michael, Coxeter, Peter, Carle, Chelsea, Onyeka, Tonia, Rewais, Isabel, Monroy Iglesias, Maria J., Vives, Nuria, Wei, Feixue, Abila, Derrick Bary, Carreras, Giulia, Santero, Marilina, O'Dowd, Emma L., Lui, Gigi, Tolani, Musliu Adetola, Mullooly, Maeve, Lee, Shing Fung, Landy, Rebecca, Hanley, Sharon J.B., Binefa, Gemma, McShane, Charlene M., Gizaw, Muluken, Selvamuthu, Poongulali, Boukheris, Houda, Nakaganda, Annet, Ergin, Isil, Moraes, Fabio Ynoe, Timilshina, Nahari, Kumar, Ashutosh, Vale, Diama B., Molina-Barceló, Ana, Force, Lisa M., Campbell, Denise Joan, Wang, Yuqing, Wan, Fang, Baker, Anna Lisa, Singh, Ramnik, Salam, Rehana Abdus, Yuill, Susan, Shah, Richa, Lansdorp-Vogelaar, Iris, Yusuf, Aasim, Aggarwal, Ajay, Murillo, Raul, Torode, Julie S., Kliewer, Erich V., Bray, Freddie, Chan, Kelvin K.W., Peacock, Stuart, Hanna, Timothy P., Ginsburg, Ophira, Van Hemelrijck, Mieke, Sullivan, Richard, Roitberg, Felipe, Ilbawi, André M., Soerjomataram, Isabelle, Canfell, Karen, Steinberg, Julia, Hughes, Suzanne, Hui, Harriet, Allsop, Matthew J., Egger, Sam, David, Michael, Caruana, Michael, Coxeter, Peter, Carle, Chelsea, Onyeka, Tonia, Rewais, Isabel, Monroy Iglesias, Maria J., Vives, Nuria, Wei, Feixue, Abila, Derrick Bary, Carreras, Giulia, Santero, Marilina, O'Dowd, Emma L., Lui, Gigi, Tolani, Musliu Adetola, Mullooly, Maeve, Lee, Shing Fung, Landy, Rebecca, Hanley, Sharon J.B., Binefa, Gemma, McShane, Charlene M., Gizaw, Muluken, Selvamuthu, Poongulali, Boukheris, Houda, Nakaganda, Annet, Ergin, Isil, Moraes, Fabio Ynoe, Timilshina, Nahari, Kumar, Ashutosh, Vale, Diama B., Molina-Barceló, Ana, Force, Lisa M., Campbell, Denise Joan, Wang, Yuqing, Wan, Fang, Baker, Anna Lisa, Singh, Ramnik, Salam, Rehana Abdus, Yuill, Susan, Shah, Richa, Lansdorp-Vogelaar, Iris, Yusuf, Aasim, Aggarwal, Ajay, Murillo, Raul, Torode, Julie S., Kliewer, Erich V., Bray, Freddie, Chan, Kelvin K.W., Peacock, Stuart, Hanna, Timothy P., Ginsburg, Ophira, Van Hemelrijck, Mieke, Sullivan, Richard, Roitberg, Felipe, Ilbawi, André M., Soerjomataram, Isabelle, and Canfell, Karen

Abstract

While previous reviews found a positive association between pre-existing cancer diagnosis and COVID-19-related death, most early studies did not distinguish long-term cancer survivors from those recently diagnosed/treated, nor adjust for important confounders including age. We aimed to consolidate higher-quality evidence on risk of COVID-19-related death for people with recent/active cancer (compared to people without) in the pre-COVID-19-vaccination period. We searched the WHO COVID-19 Global Research Database (20 December 2021), and Medline and Embase (10 May 2023). We included studies adjusting for age and sex, and providing details of cancer status. Risk-of-bias assessment was based on the Newcastle-Ottawa Scale. Pooled adjusted odds or risk ratios (aORs, aRRs) or hazard ratios (aHRs) and 95% confidence intervals (95% CIs) were calculated using generic inverse-variance random-effects models. Random-effects meta-regressions were used to assess associations between effect estimates and time since cancer diagnosis/treatment. Of 23 773 unique title/abstract records, 39 studies were eligible for inclusion (2 low, 17 moderate, 20 high risk of bias). Risk of COVID-19-related death was higher for people with active or recently diagnosed/treated cancer (general population: aOR = 1.48, 95% CI: 1.36-1.61, I2 = 0; people with COVID-19: aOR = 1.58, 95% CI: 1.41-1.77, I2 = 0.58; inpatients with COVID-19: aOR = 1.66, 95% CI: 1.34-2.06, I2 = 0.98). Risks were more elevated for lung (general population: aOR = 3.4, 95% CI: 2.4-4.7) and hematological cancers (general population: aOR = 2.13, 95% CI: 1.68-2.68, I2 = 0.43), and for metastatic cancers. Meta-regression suggested risk of COVID-19-related death decreased with time since diagnosis/treatment, for example, for any/solid cancers, fitted aOR = 1.55 (95% CI: 1.37-1.75) at 1 year and aOR = 0.98 (95% CI: 0.80-1.20) at 5 years post-cancer diagnosis/treatment. In conclusion, before CO

Published
2024

17. Utilising systematic reviews to assess potential overtreatment and claim for better evidence-based research: an analysis of anticancer drugs versus supportive care in advanced esophageal cancer.

Author

Santero, Marilina, Meade, Adriana-Gabriela, Selva, Anna, Savall-Esteve, Olga, Bracchiglione, Javier, Macías, Ismael, Leache, Leire, Cerdà, Paula, Bonfill Cosp, Xavier, Appropriateness of Systemic Oncological Treatments for Advanced Cancer (ASTAC-Study) Research Group, Acosta-Dighero, Roberto, Antequera, Alba, Auladell-Rispau, Ariadna, Cantero-Fortiz, Yahveth, Hernández, Edgar D, Irassar, Juan, Meinardi, Pamela, Merchán-Galvis, Angela, Meza, Nicolas, and Quintana, María Jesús

Subjects
*ESOPHAGEAL cancer, *ANTINEOPLASTIC agents, *DRUG analysis, *RANDOMIZED controlled trials, *ESOPHAGECTOMY, *CANCER patient care, *OVERALL survival
Abstract

Background: Highlighting the identified gaps in evidence-based research concerning advanced esophageal cancer (EC) treatment and care, this review evaluates the efficacy and safety of anticancer drugs compared to supportive care for advanced EC patients, aiming to assess the appropriateness of usual treatments and identify the gaps that need to be filled with primary research. Methods: We searched (May 2022) MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials (CENTRAL), Epistemonikos, and trial registries (ClinicalTrials.gov and PROSPERO) for randomised controlled trials (RCTs) comparing anticancer drugs (chemotherapy, immunotherapy, or biological/targeted therapy) with supportive care in advanced EC. The results were summarised using GRADE summary of finding tables. Results: We included 15 RCTs. Most studies did not have a special focus on EC, did not detail the treatment lines in all patients, and did not evaluate all outcomes. Anticancer drugs may result in a slight increase in overall survival (OS) (HR 0.78; 95% CI 0.71, 0.86; MD 0.83 months) and better progression-free survival (PFS) (HR 0.56 95% CI 0.49, 0.64, MD 0.68 months), but also may increase toxicity (RR 1.37; 95% CI 1.13, 1.65), without a significant improvement in quality of life. The certainty of evidence was low or very low due to indirectness of results and lack of specific focus on EC in some studies. Conclusion: RCTs on advanced EC lack specificity, detailed treatment line information, and evaluation of all relevant outcomes. Moreover, when they find any benefit, this is negligible. Therefore, the certainty to justify anticancer drug treatments instead of supportive care in advanced EC is low or very low, and this information should be actively shared with affected patients. More and better RCTs should be conducted to assess whether any old or new proposed treatment for advanced EC patients provides a better balance of benefits and harms than the supportive care. Systematic review registration: The study protocol was registered in OSF (https://doi.org/10.17605/OSF.IO/7CHX6) on 2022–03-29. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

18. Effectiveness and Cost-Effectiveness of Self-Management Interventions for Adults Living with Heart Failure to Improve Patient-Important Outcomes: An Evidence Map of Randomized Controlled Trials

Author

Santero, Marilina, primary, Song, Yang, additional, Beltran, Jessica, additional, Medina-Aedo, Melixa, additional, Canelo-Aybar, Carlos, additional, Valli, Claudia, additional, Rocha, Claudio, additional, León-García, Montserrat, additional, Salas-Gama, Karla, additional, Kaloteraki, Chrysoula, additional, Niño de Guzmán, Ena, additional, Ballester, Marta, additional, González-González, Ana Isabel, additional, Poortvliet, Rune, additional, van der Gaag, Marieke, additional, Spoiala, Cristina, additional, Gurung, Pema, additional, Willemen, Fabienne, additional, Cools, Iza, additional, Bleeker, Julia, additional, Kancheva, Angelina, additional, Ertl, Julia, additional, Laure, Tajda, additional, Kancheva, Ivana, additional, Pacheco-Barrios, Kevin, additional, Zafra-Tanaka, Jessica Hanae, additional, Tsokani, Sofia, additional, Veroniki, Areti Angeliki, additional, Seitidis, Georgios, additional, Christogiannis, Christos, additional, Kontouli, Katerina Maria, additional, Groene, Oliver, additional, Sunol, Rosa, additional, Orrego, Carola, additional, Heijmans, Monique, additional, and Alonso-Coello, Pablo, additional

Published
2024
Full Text
View/download PDF

20. Self-Management Interventions for Adults Living with Type II Diabetes to Improve Patient-Important Outcomes: An Evidence Map

Author

Song, Yang, primary, Beltran Puerta, Jessica, additional, Medina-Aedo, Melixa, additional, Canelo-Aybar, Carlos, additional, Valli, Claudia, additional, Ballester, Marta, additional, Rocha, Claudio, additional, Garcia, Montserrat León, additional, Salas-Gama, Karla, additional, Kaloteraki, Chrysoula, additional, Santero, Marilina, additional, Niño de Guzmán, Ena, additional, Spoiala, Cristina, additional, Gurung, Pema, additional, Willemen, Fabienne, additional, Cools, Iza, additional, Bleeker, Julia, additional, Poortvliet, Rune, additional, Laure, Tajda, additional, Gaag, Marieke van der, additional, Pacheco-Barrios, Kevin, additional, Zafra-Tanaka, Jessica, additional, Mavridis, Dimitris, additional, Angeliki Veroniki, Areti, additional, Zevgiti, Stella, additional, Seitidis, Georgios, additional, Alonso-Coello, Pablo, additional, Groene, Oliver, additional, González-González, Ana Isabel, additional, Sunol, Rosa, additional, Orrego, Carola, additional, and Heijmans, Monique, additional

Published
2023
Full Text
View/download PDF

21. Risk of COVID‐19 death for people with a pre‐existing cancer diagnosis prior to COVID‐19‐vaccination: A systematic review and meta‐analysis

Author

Steinberg, Julia, primary, Hughes, Suzanne, additional, Hui, Harriet, additional, Allsop, Matthew J., additional, Egger, Sam, additional, David, Michael, additional, Caruana, Michael, additional, Coxeter, Peter, additional, Carle, Chelsea, additional, Onyeka, Tonia, additional, Rewais, Isabel, additional, Monroy Iglesias, Maria J., additional, Vives, Nuria, additional, Wei, Feixue, additional, Abila, Derrick Bary, additional, Carreras, Giulia, additional, Santero, Marilina, additional, O'Dowd, Emma L., additional, Lui, Gigi, additional, Tolani, Musliu Adetola, additional, Mullooly, Maeve, additional, Lee, Shing Fung, additional, Landy, Rebecca, additional, Hanley, Sharon J. B., additional, Binefa, Gemma, additional, McShane, Charlene M., additional, Gizaw, Muluken, additional, Selvamuthu, Poongulali, additional, Boukheris, Houda, additional, Nakaganda, Annet, additional, Ergin, Isil, additional, Moraes, Fabio Ynoe, additional, Timilshina, Nahari, additional, Kumar, Ashutosh, additional, Vale, Diama B., additional, Molina‐Barceló, Ana, additional, Force, Lisa M., additional, Campbell, Denise Joan, additional, Wang, Yuqing, additional, Wan, Fang, additional, Baker, Anna‐Lisa, additional, Singh, Ramnik, additional, Salam, Rehana Abdus, additional, Yuill, Susan, additional, Shah, Richa, additional, Lansdorp‐Vogelaar, Iris, additional, Yusuf, Aasim, additional, Aggarwal, Ajay, additional, Murillo, Raul, additional, Torode, Julie S., additional, Kliewer, Erich V., additional, Bray, Freddie, additional, Chan, Kelvin K. W., additional, Peacock, Stuart, additional, Hanna, Timothy P., additional, Ginsburg, Ophira, additional, Van Hemelrijck, Mieke, additional, Sullivan, Richard, additional, Roitberg, Felipe, additional, Ilbawi, André M., additional, Soerjomataram, Isabelle, additional, and Canfell, Karen, additional

Published
2023
Full Text
View/download PDF

22. Anticancer Drugs Compared to No Anticancer Drugs in Patients with Advanced Hepatobiliary Cancer: A Mapping Review and Evidence Gap Map

Author

Requeijo, Carolina, primary, Bracchiglione, Javier, additional, Meza, Nicolás, additional, Acosta-Dighero, Roberto, additional, Salazar, Josefina, additional, Santero, Marilina, additional, Meade, Adriana-G, additional, Quintana, María Jesús, additional, Rodríguez-Grijalva, Gerardo, additional, Selva, Anna, additional, Solà, Ivan, additional, Urrútia, Gerard, additional, and Bonfill Cosp, Xavier, additional

Published
2023
Full Text
View/download PDF

26. Risk of COVID‐19 death for people with a pre‐existing cancer diagnosis prior to COVID‐19‐vaccination: A systematic review and meta‐analysis.

Author

Steinberg, Julia, Hughes, Suzanne, Hui, Harriet, Allsop, Matthew J., Egger, Sam, David, Michael, Caruana, Michael, Coxeter, Peter, Carle, Chelsea, Onyeka, Tonia, Rewais, Isabel, Monroy Iglesias, Maria J., Vives, Nuria, Wei, Feixue, Abila, Derrick Bary, Carreras, Giulia, Santero, Marilina, O'Dowd, Emma L., Lui, Gigi, and Tolani, Musliu Adetola

Abstract

While previous reviews found a positive association between pre‐existing cancer diagnosis and COVID‐19‐related death, most early studies did not distinguish long‐term cancer survivors from those recently diagnosed/treated, nor adjust for important confounders including age. We aimed to consolidate higher‐quality evidence on risk of COVID‐19‐related death for people with recent/active cancer (compared to people without) in the pre‐COVID‐19‐vaccination period. We searched the WHO COVID‐19 Global Research Database (20 December 2021), and Medline and Embase (10 May 2023). We included studies adjusting for age and sex, and providing details of cancer status. Risk‐of‐bias assessment was based on the Newcastle‐Ottawa Scale. Pooled adjusted odds or risk ratios (aORs, aRRs) or hazard ratios (aHRs) and 95% confidence intervals (95% CIs) were calculated using generic inverse‐variance random‐effects models. Random‐effects meta‐regressions were used to assess associations between effect estimates and time since cancer diagnosis/treatment. Of 23 773 unique title/abstract records, 39 studies were eligible for inclusion (2 low, 17 moderate, 20 high risk of bias). Risk of COVID‐19‐related death was higher for people with active or recently diagnosed/treated cancer (general population: aOR = 1.48, 95% CI: 1.36‐1.61, I2 = 0; people with COVID‐19: aOR = 1.58, 95% CI: 1.41‐1.77, I2 = 0.58; inpatients with COVID‐19: aOR = 1.66, 95% CI: 1.34‐2.06, I2 = 0.98). Risks were more elevated for lung (general population: aOR = 3.4, 95% CI: 2.4‐4.7) and hematological cancers (general population: aOR = 2.13, 95% CI: 1.68‐2.68, I2 = 0.43), and for metastatic cancers. Meta‐regression suggested risk of COVID‐19‐related death decreased with time since diagnosis/treatment, for example, for any/solid cancers, fitted aOR = 1.55 (95% CI: 1.37‐1.75) at 1 year and aOR = 0.98 (95% CI: 0.80‐1.20) at 5 years post‐cancer diagnosis/treatment. In conclusion, before COVID‐19‐vaccination, risk of COVID‐19‐related death was higher for people with recent cancer, with risk depending on cancer type and time since diagnosis/treatment. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

29. Quality improvement intervention to increase colorectal cancer screening at the primary care setting: a cluster-randomised controlled trial

Author

Irazola, Vilma, primary, Santero, Marilina, additional, Sanchez, Mario, additional, Tristao, Ignez, additional, Ruiz, Juan Ignacio, additional, Spira, Cintia, additional, Ismael, Julia, additional, Cavallo, Ana Soledad, additional, Gutierrez, Laura, additional, Mazzaresi, Yanina, additional, Nadal, Ana Maria, additional, and García Elorrio, Ezequiel, additional

Published
2023
Full Text
View/download PDF

32. Anticancer Drugs Compared to No Anticancer Drugs in Patients with Advanced Hepatobiliary Cancer: A Mapping Review and Evidence Gap Map

Author

Requeijo,Carolina, Bracchiglione,Javier, Meza,Nicolás, Acosta-Dighero,Roberto, Salazar,Josefina, Santero,Marilina, Meade,Adriana-G, Quintana,María Jesús, Rodríguez-Grijalva,Gerardo, Selva,Anna, Solà ,Ivan, Urrútia,Gerard, Bonfill Cosp,Xavier, Requeijo,Carolina, Bracchiglione,Javier, Meza,Nicolás, Acosta-Dighero,Roberto, Salazar,Josefina, Santero,Marilina, Meade,Adriana-G, Quintana,María Jesús, Rodríguez-Grijalva,Gerardo, Selva,Anna, Solà ,Ivan, Urrútia,Gerard, and Bonfill Cosp,Xavier

Abstract

Carolina Requeijo,1,* Javier Bracchiglione,1– 3,* Nicolás Meza,2 Roberto Acosta-Dighero,2 Josefina Salazar,1 Marilina Santero,1 Adriana-G Meade,1 María Jesús Quintana,1,3,4 Gerardo Rodríguez-Grijalva,1 Anna Selva,3,5 Ivan Solà ,1,3 Gerard Urrútia,1,3 Xavier Bonfill Cosp1,3,4 On behalf of Appropriateness of Systemic Oncological Treatments for Advanced Cancer (ASTAC) Research Group1Iberoamerican Cochrane Centre, Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona, Spain; 2Interdisciplinary Centre for Health Studies (CIESAL), Valparaiso University, Viña del Mar, Chile; 3CIBER of Epidemiology and Public Health (CIBERESP), Barcelona, Spain; 4Autonomous University of Barcelona, Barcelona, Spain; 5Clinical Epidemiology and Cancer Screening, Parc Taulí Hospital Universitari, Parc Taulí Research and Innovation Institute Foundation (I3PT-CERCA), Autonomous University of Barcelona, Sabadell, Spain*These authors contributed equally to this workCorrespondence: Carolina Requeijo, Iberoamerican Cochrane Centre, Biomedical Research Institute Sant Pau (IIB Sant Pau), C/ Sant Antoni M. Claret 167. Pavelló 18 planta 0. 08025, Barcelona, Spain, Email crequeijo@santpau.catIntroduction: Despite being commonly recommended, the impact of anticancer drugs (ACDs) on patient-important outcomes beyond survival for advanced hepatobiliary cancers (HBCs) may not have been sufficiently assessed. We aim to identify and map the evidence regarding ACDs versus best supportive care (BSC) for advanced HBCs, considering patient-centered outcomes.Methods: In this mapping review, we included systematic reviews, randomized controlled trials, quasi-experimental, and observational studies comparing ACDs (chemotherapy, immunotherapy, biological/targeted therapy) versus BSC for advanced HBCs. We searched MEDLINE (PubMed), EMBASE (Ovid), Cochrane Library, Epistemonikos, PROSPERO and clinicaltrials.gov for eligible studies. Two reviewers performed the screening and

Published
2023

34. Systemic Oncological Treatments versus Supportive Care for Patients with Advanced Hepatobiliary Cancers: An Overview of Systematic Reviews

Author

Bracchiglione, Javier, primary, Rodríguez-Grijalva, Gerardo, additional, Requeijo, Carolina, additional, Santero, Marilina, additional, Salazar, Josefina, additional, Salas-Gama, Karla, additional, Meade, Adriana-Gabriela, additional, Antequera, Alba, additional, Auladell-Rispau, Ariadna, additional, Quintana, María Jesús, additional, Solà, Ivan, additional, Urrútia, Gerard, additional, Acosta-Dighero, Roberto, additional, and Bonfill Cosp, Xavier, additional

Published
2023
Full Text
View/download PDF

37. Programs for optimizing the use of antibiotics (PROA) and their implementation in Argentina's healthcare system

Author

Santero, Marilina, Menai, Samanta Díaz, and Gregorio, Sofia

Subjects
Environmental Public Health, Medical Sciences, Epidemiology, Other Public Health, Medicine and Health Sciences, Community Health and Preventive Medicine, Clinical Epidemiology, Public Health, Health Services Research, Health Services Administration
Abstract

This study aims to identify and characterize the currently published evidence on programs for optimizing the use of antibiotics initiatives and their implementation in the health care system of Argentina, focusing on how the impact of these programs was measured

Published
2023
Full Text
View/download PDF

38. Inappropriate use of clinical practices in Spain: A scoping review protocol

Author

Esteve, Olga Savall, Santero, Marilina, Lesmes, Irene Breton, Lazo, Camila Ignacia Quirland, Valera, Maria Rubio, Lou, Ignacio Aznar, Valencia, Marta Gutiérrez, Bonfill, Xavier, Solà, Ivan, Leache, Leire, De Miguel Diez, Javier, Requeijo, Carolina, De La Torre Pérez, Laura, and Alamo Junquera, Maria Dolors

Subjects
Medicine and Health Sciences, Public Health, Health Services Research, appropriateness
Abstract

Updated version of the scoping review protocol of potentially inappropriate practices in Spain.

Published
2023
Full Text
View/download PDF

39. Quality assessment of economic evaluations: protocol for a content analysis study

Author

Ruiz, Francis, Reyes, María Ximena Rojas, Morgan, Rebecca L., Santero, Marilina, Heupnik, Lieke Fleur, Alonso-Coello, Pablo, Xie, Feng, Vale, Luke, Lazo, Camila Ignacia Quirland, Van Mastrigt, Ghislaine Anna Pauline Gemma, De La Torre-Pérez, Laura, and Heifez, Melissa

Subjects
Medicine and Health Sciences, Quality Economic evaluations, Health economics, Content anlaysis of checklists
Abstract

Content analysis of checklists assessing the quality of economic evaluations.

Published
2023
Full Text
View/download PDF

40. Which Checklists assess MEthodological limitations of EConomic Analyses in Health?: a scoping review protocol

Author

Morgan, Rebecca L., Van Mastrigt, Ghislaine Anna Pauline Gemma, De La Torre-Pérez, Laura, Alonso-Coello, Pablo, Santero, Marilina, Heifez, Melissa, Lazo, Camila Ignacia Quirland, Solà, Ivan, Menai, Samanta Díaz, and Gregorio, Sofia

Subjects
Cost-utility, Scoping review, Cost estimation, Budget impact analysis, Resource use, Costing, Economic analysis, Cost-effectiveness analyses, Guideline, Evidence map, Health Economics, Cost-minimization analysis, Risk of Bias, Medicine and Health Sciences, Systematic review, Methodological quality, Methodological limitations, Quality assessment
Abstract

Scoping review to identify and characterize the available instruments or tools developed to assess the quality of economic analyses in health.

Published
2023
Full Text
View/download PDF

42. GECEA: A cost-effective modeling study of treatments for advanced esophageal cancer in Spain

Author

Santero, Marilina, Alonso-Coello, Pablo, Lazo, Camila Ignacia Quirland, and De La Torre-Pérez, Laura

Subjects
supportive care, Medicine and Health Sciences, advanced cancer, health economics, esophageal cancer
Abstract

This study aims to evaluate the cost-effectiveness of different treatment alternatives for advanced EC in Spain, using a modeling approach. The results of this study could inform clinical decision-making and resource allocation, ultimately improving patient outcomes while reducing healthcare costs.

Published
2023
Full Text
View/download PDF

46. HOSPITAL DE LA SANTA CREU I SANT PAU

Author

Santafe, Angie, Rojas- Reyes, María, Bendersky, Josefina, Urrutia, Gerard, Santero, Marilina, Verdugo, Francisca, Jimenez, Elena, and Vargas, Laura

Subjects
Evidence-based medicine, Epistemonikos L.OVE Platform, Inform Health Decisions, capacity building, Evidence Synthesis, knowledge transfer, Continuos update, Living Evidence
Abstract

Esta carpeta contiene los documentos de los proyectos "Eficacia y Seguridad de Terapias de presión negativa para heridas" y "Efectividad y seguridad de la terapia dirigida en pacientes con cáncer avanzado de ovario: protocolo de revisión panorámica (overview)." como parte del proyecto LE-IHD

Published
2022
Full Text
View/download PDF

48. Effectiveness and safety of targeted therapy in patients with advanced ovarian cancer: Living overview of systematic reviews (Protocol)

Author

Santero, Marilina, Urrutia, Gerard, Santafe, Angie, Jimenez, Elena, Vargas, Laura, Rojas- Reyes, María, and Open Science Framework

Subjects
Living overview, advance ovarian cancer, Living evidence, Medicine and Health Sciences, targeted therapy
Abstract

The proliferation of studies and systematic reviews evaluating the efficacy of biological or targeted therapy for the management of advanced ovarian cancer has increased in recent years with the incorporation of new drugs. To date, fourteen systematic reviews have been identified that answer questions related to this type of therapy in ovarian cancer, which have been summarized in an overview. However, it is expected that in the forthcoming months, new studies will emerge assessing the effectiveness and safety of biological agents (Bevacizumab, Olaparib, Niraparib, Rucaparib) in this type of therapy for patients with advanced ovarian cancer. Therefore, it is considered pertinent to carry out a live systematic review that allows synthesizing the emerging evidence, with the aim of estimating with greater precision the effect of the different biological agents on the outcomes: survival, disease-free progression, toxicity, disease-related symptoms, and quality of life. In order to, work will be done on the identification, evaluation, and synthesis of the new evidence through periodic monitoring during the next eight months, based on the tools provided for this purpose as part of the "Living evidence to inform health decisions" Project.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results